$36.70
-10%Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.
Last Annual Value
205.71M
3-Year CAGR
23%
5-Year CAGR
13%
10-Year CAGR
6%
| Company | Net Cash Provided by Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
![]() Sionna Therapeutics, Inc. NASDAQ:SION | 205.71M | 1779.2% | N/A | N/A | |
![]() Vera Therapeutics, Inc. NASDAQ:VERA | 308.90M | 32.3% | 41.8% | N/A | |
![]() Janux Therapeutics, Inc. NASDAQ:JANX | 4.95M | -56.4% | -58.2% | N/A | |
![]() Maze Therapeutics, Inc. NASDAQ:MAZE | 275.34M | 156.1% | N/A | N/A | |
![]() Ardelyx, Inc. NASDAQ:ARDX | 54.51M | -28.0% | -8.1% | -11.8% | |
![]() Celldex Therapeutics, Inc. NASDAQ:CLDX | 2.39M | -77.8% | -61.2% | -16.5% | |
![]() Immunome, Inc. NASDAQ:IMNM | 640.36M | 76.5% | 87.3% | N/A | |
![]() Xeris Biopharma Holdings, Inc. NASDAQ:XERS | 11.39M | N/A | -16.0% | 11.3% | |
![]() Biohaven Ltd. NYSE:BHVN | 439.12M | 27.5% | 26.0% | N/A |
Continue your SION research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.